PatrickFordeMD

Oncology • Baltimore, MD

Thoracic Cancer

Professor of Oncology, Johns Hopkins University School of Medicine

Join to view full profile

Dr. Forde is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Forde's full profile

Already have an account?

Office
201 N. Broadway
Baltimore, MD 21287
Phone+1 410-955-8893

Fax+1 410-614-9334
Is this information wrong?

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2011 - 2014
Royal College of Surgeons IrelandClass of 2004

Certifications & Licensure

MD State Medical License 2014 - 2024

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014

Clinical Trials

Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies Start of enrollment: 2015 Nov 23
Terminated
Phase 1, Phase 2
Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma Start of enrollment: 2017 Jun 13
Completed
Phase 2
Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer Start of enrollment: 2017 Dec 12
Active, not recruiting
Phase 2
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma Start of enrollment: 2019 Oct 02
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Neoadjuvant Chemoimmunotherapy for NSCLC: A Systematic Review and Meta-Analysis.
Mark Sorin, Connor Prosty, Louis Ghaleb, Kathy Nie, Khaled Katergi, Muhammad H Shahzad, Laurie-Rose Dubé, Aline Atallah, Anikka Swaby, Matthew Dankner, Trafford Crump,...> ;JAMA Oncology. 2024 Mar 21
Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC.
Mari Nakazawa, Guilherme Harada, Paola Ghanem, Adrian Bubie, Lesli A Kiedrowski, Joseph C Murray, Kristen A Marrone, Susan C Scott, Stefanie Houseknecht, Christina J F...> ;Cancer Research Communications. 2024 Mar 14
Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Che...
Jacobi B Hines, Robert B Cameron, Alessandra Esposito, Leeseul Kim, Luca Porcu, Antonio Nuccio, Giuseppe Viscardi, Roberto Ferrara, Giulia Veronesi, Patrick M Forde, J...> ;Journal of Thoracic Oncology. 2024 Mar 8
1 citations
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.
Benjamin Besse, Elvire Pons-Tostivint, Keunchil Park, Sylvia Hartl, Patrick M Forde, Maximilian J Hochmair, Mark M Awad, Michael Thomas, Glenwood Goss, Paul Wheatley-P...> ;Nature Medicine. 2024 Mar 1
The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer.
Dunne, E., Fick, C., Isbell, J., Chaft, J., Altorki, N., Park, B., Spicer, J., Forde, P., Gomez, D., Iyengar, P., Harpole, D., Stinchcombe, T., Liberman, M., Bott, M.,...> ;The Annals of Thoracic Surgery. 2024 Feb 3
1 citations
Elucidating the Heterogeneity of Immunotherapy Response and Immune-Related Toxicities by Longitudinal ctDNA and Immune Cell Compartment Tracking in Lung Cancer.
Murray, J., Sivapalan, L., Hummelink, K., Balan, A., White, J., Niknafs, N., Rhymee, L., Pereira, G., Rao, N., Weksler, B., Bahary, N., Phallen, J., Leal, A., Bartlett...> ;Clinical Cancer Research. 2024 Jan 17
Clinical and Genomic Characterization of Long-Term Responders Receiving Immune Checkpoint Blockade for Metastatic Non-Small-Cell Lung Cancer.
Paola Ghanem, Joseph C Murray, Melinda Hsu, Matthew Z Guo, David S Ettinger, Josephine Feliciano, Patrick Forde, Christine L Hann, Vincent K Lam, Benjamin Levy, Valsam...> ;Clinical Lung Cancer. 2024 Mar 1
4 citations
Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial.
Tina Cascone, Gozde Kar, Jonathan D Spicer, Rosario García-Campelo, Walter Weder, Davey B Daniel, David R Spigel, Maen Hussein, Julien Mazieres, Julio Oliveira, Edwin ...> ;Cancer Discovery. 2023 Nov 1
4 citations
Association between pathologic response and survival after neoadjuvant therapy in lung cancer.
Julie Stein Deutsch, Ashley Cimino-Mathews, Elizabeth Thompson, Mariano Provencio, Patrick M Forde, Jonathan Spicer, Nicolas Girard, Daphne Wang, Robert A Anders, Edwa...> ;Nature Medicine. 2024 Jan 1
1 citations
Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systemat...
Daniele Marinelli, Filippo Tommaso Gallina, Sergio Pannunzio, Mattia Alberto Di Civita, Andrea Torchia, Raffaele Giusti, Alain Jonathan Gelibter, Michela Roberto, Moni...> ;Critical Reviews in Oncology/hematology. 2023 Dec 1
1 citations
A Brief Report on the Patterns of Mediastinal Nodal Failure in Resectable Stage IB-IIIA NSCLC Treated With Neoadjuvant Immunotherapy Combinations, a Secondary Analysis...
Serena Mao, Samuel Rosner, Patrick M Forde, Jamie E Chaft, David R Jones, Jonathan Spicer, Russell Kenneth Hales, Jinny Suk Ha, Chen Hu, Khinh Ranh Voong> ;Clinical Lung Cancer. 2024 Jan 1
Improved lung cancer clinical outcomes in patients with autoimmune rheumatic diseases.
Paola Ghanem, Joseph C Murray, Kristen A Marrone, Susan C Scott, Josephine L Feliciano, Vincent K Lam, Christine L Hann, David S Ettinger, Benjamin P Levy, Patrick M F...> ;RMD Open. 2023 Oct 1
Ablative radiation alone in stage I lung cancer produces an adaptive systemic immune response: insights from a prospective stud.
Khinh Ranh Voong, Peter B Illei, Bradley Presson, Dipika Singh, Zhen Zeng, Mara Lanis, Russell K Hales, Chen Hu, Phuoc T Tran, Christos Georgiades, Cheng Ting Lin, Jef...> ;Journal for Immunotherapy of Cancer. 2023 Oct 1
2 citations
Non-invasive PD-L1 quantification using [F]DK222-PET imaging in cancer immunotherapy.
Akhilesh Mishra, Kuldeep Gupta, Dhiraj Kumar, Gabriela Lofland, Ajay Kumar Sharma, Lilja B Solnes, Steven P Rowe, Patrick M Forde, Martin G Pomper, Edward W Gabrielson...> ;Journal for Immunotherapy of Cancer. 2023 Oct 1
6 citations
Lung tumor-infiltrating Thave divergent transcriptional profiles and function linked to checkpoint blockade response.
Li, T., Li, T., Arbor G Dykema, Jiajia Zhang, Laurene S Cheung, Sydney Connor, Boyang Zhang, Zhen Zeng, Christopher M Cherry, Taibo Li, Justina X Caushi, Marni Nishimo...> ;Science Immunology. 2023 Sep 15
1 citations
Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer.
Khaled Sanber, Samuel Rosner, Patrick M Forde, Kristen A Marrone> ;Biodrugs. 2023 Nov 1
18 citations
Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy.
Suzanne L Topalian, Patrick M Forde, Leisha A Emens, Mark Yarchoan, Kellie N Smith, Drew M Pardoll> ;Cancer Cell. 2023 Sep 11
Neoadjuvant immunotherapy in resectable non-small cell lung cancer.
Sarah E Lochrin, Patrick M Forde> ;Clinical Advances in Hematology & Oncology. 2023 Aug 1
Neoadjuvant immune checkpoint inhibitor therapy in resectable non-small cell lung cancer.
Michael R Conroy, Colum Dennehy, Patrick M Forde> ;Lung Cancer. 2023 Sep 1
15 citations
Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges.
Giannis Mountzios, Jordi Remon, Lizza E L Hendriks, Rosario García-Campelo, Christian Rolfo, Paul Van Schil, Patrick M Forde, Benjamin Besse, Vivek Subbiah, Martin Rec...> ;Nature Reviews. Clinical Oncology. 2023 Oct 1
Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs.
Tian Zhang, Patrick M Forde, Ryan J Sullivan, Elad Sharon, Elizabeth Barksdale, Wendy Selig, Scot Ebbinghaus, Gina Fusaro, Damla Gunenc, Dena Battle, Robyn Burns, Marc...> ;Journal for Immunotherapy of Cancer. 2023 May 1
10 citations
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer.
Arvind Ravi, Matthew D Hellmann, Monica B Arniella, Mark Holton, Samuel S Freeman, Vivek Naranbhai, Chip Stewart, Ignaty Leshchiner, Jaegil Kim, Yo Akiyama, Aaron T Gr...> ;Nature Genetics. 2023 May 1
2 citations
Advancing neoadjuvant immunotherapy for lung cancer.
Michael Conroy, Patrick M Forde> ;Nature Medicine. 2023 Mar 1
1 citations
Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancer.
Patrick M Forde, Jonathan Spicer, Shun Lu, Mariano Provencio, Tetsuya Mitsudomi, Mark M Awad, Enriqueta Felip, Stephen R Broderick, Julie R Brahmer, Scott J Swanson, K...> ;Future Oncology. 2023 Mar 1
13 citations
Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non-Small Cell Lung Cancer.
Samuel Rosner, Joshua E Reuss, Marianna Zahurak, Jiajia Zhang, Zhen Zeng, Janis Taube, Valsamo Anagnostou, Kellie N Smith, Joanne Riemer, Peter B Illei, Stephen R Brod...> ;Clinical Cancer Research. 2023 Feb 16
Join now to see all

Journal Articles

Immuno-Oncology Trial Endpoints: Capturing Clinically Meaningful Activity
Elad Sharon, Patrick M Forde, Valsamo Anagnostou, Hao Wang, Franco Verde, Mark Yarchoan, Clinical Cancer Research

Press Mentions

Press Release: ECOG-ACRIN Announces the Recipients of Its 2023 Scientific Leadership and Mentorship AwardsMay 17th, 2023
Nivolumab Improves Survival in 80% of Trial Participants with Common Lung CancerFebruary 21st, 2023
Neoadjuvant Nivolumab Shows Long-Term Benefit in Patients with Non-Small Cell Lung CancerFebruary 15th, 2023
Join now to see all